Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 901-908

  Parhofer, Klaus G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dyslipoproteinemia; Flushing; Hyperlipidemia; Nicotinic acid

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN PLUS NIACIN; COLESEVELAM; COLESTIPOL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NIACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIACIN PLUS ROSUVASTATIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; APPETITE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; REVIEW; SIDE EFFECT; STROKE;

EID: 74049112916     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s4502     Document Type: Review

References (53)

1. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
2. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
4. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis. Lancet. 2008;371:117-125.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007;28:2375-2414.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2009. Diab Care. 2009;32 S1:S13-S61.
8. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54:558-559.
9. Vogt A, Kassner U, Hostalek U, et al. Evaluations of safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS Study. Curr Med Res Opin. 2006;22:417-425.
10. Shepherd J, Packard DJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolism. J Clin Invest. 1979;63:858-867.
11. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
12. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360.
13. Carlson LA Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405.
14. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432-437.
15. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan):a long-term study. Am J Cardiol. 1998;82:74U-81U.
16. Kamanna VS, Ganji SH, Kashyap ML. Niacin:an old drug rejuvenated. Curr Atheroscler Rep. 2009;11:45-51.
17. Benyo Z, Gille A, Kero J. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115:3634-2640.
18. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand. 1962;172:641-645.
19. Carlson LA. Nicotinic acid: the broad spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258:94-114.
20. Van JT, Pan J, Wasty T, et al. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol. 2002;89:1306.
21. Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009;11:67-70.
22. Brown BG, Zhao XQ Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
23. Canner PL, Berge KH, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245.
24. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
25. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
26. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;11:2243-2250.
27. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target:a systematic review. JAMA. 2007;298:786-798.
28. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93:307-312.
29. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspeciality on Patient Compliance to Treatment (IMPACT) Study. Am J Cardiol. 2004;94:306-311.
30. Morrow JD, Awad JA, Oates JA, et al. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98:812-815.
31. Ishida H, Masuhio Y, Fukushima A, et al. Identification and characterization of novel isoforms of human DP-1:DP-1 (alpha) regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner. J Biol Chem. 2005;280:24642-24648.
32. 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682-6687.
33. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacininduced cutaneous reactions. J Gen Intern Med. 1997;12:591-596.
34. Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J, et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982;31:478-482.
35. Dunn RT, For MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 1995;2:478-480.
36. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568.
37. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254-257.
38. 2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos. 2007;35:283-292.
39. 2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro- 5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794-806.
40. Van Hecken A, Depré M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol. 2007;63:135-141.
41. Bindhu K, Maria M, Scott B, et al. Absorption, metabolism, and excretion of [14C]MK-0524, a prostaglandin D2 receptor antagonist, in humans. Drug Metab Dispos. 2007;35:1196.
42. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008;83:840-847.
43. Dishy V, Liu F, Ebel DL, Atiee GJ, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol. 2009;49:416-422.
44. Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharm Exp Ther. 2008;327:665-672.
45. Felts AS. Molecule of the month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Curr Top Med Chem. 2008;14:1310.
46. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
47. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. 2009;114:192-198.
48. McKenney J, Bays H, Koren M, et al. Safety profile of extended-release niacin/laropiprant in patients with dyslipidemia. Abstracts 77th Congress of the European Atherosclerosis Society. Atherosclerosis Suppl. 2008;9(1):194-195.
49. Maccubbin D, Bays HE, Olsson Ag, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959-1970.
50. Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16:90-97.
51. Paolini JF, Mitchel YB, Reyes R, Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625-630.
52. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther. 2009;31:115-122.
53. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract. 2009;63:151-159.